Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Medacta Group SA
  6. News
  7. Summary
    MOVE   CH0468525222

MEDACTA GROUP SA

(MOVE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Medacta extends the personalized medicine concept to total knee revision surgeries with the unique and innovative MyKnee R patient-specific solution

10/19/2021 | 01:01pm EST

EQS Group-News: Medacta Group SA / Key word(s): Product Launch Medacta extends the personalized medicine concept to total knee revision surgeries with the unique and innovative MyKnee R patient-specific solution 2021-10-19 / 19:00

-----------------------------------------------------------------------------------------------------------------------

Media release Medacta extends the personalized medicine concept to total knee revision surgeries with the unique and innovative MyKnee R patient-specific solution

CASTEL SAN PIETRO, 19 October 2021 - Medacta announces the release of MyKnee^(R) R, the newest addition to its MySolutions^(R) Personalized Ecosystem. MyKnee R is the unique-on-the-market patient-specific set of 3D-printed blocks that can be directly positioned on the failed primary implant in situ, in order to easily proceed with its replacement. Starting from a CT scan, MySolutions engineers create a 3D reconstruction of the patient's joint where a failed primary implant has been positioned. This reconstruction is then used to accurately plan the positioning of a new prosthesis, chosen from Medacta's portfolio of total knee replacement solutions, ranging from a minimum level of constraint (GMK^ (R) Sphere and GMK^(R) Primary) to semi- and fully constrained solutions (GMK^(R) Revision and GMK^(R) Hinge). MyKnee R is the game-changing technology to facilitate the introduction to total knee revision surgeries, where even highly experienced surgeons are often confronted with complex and time-consuming cases.

Regarding this aspect, Dr. Vicente Leon, the first surgeon to use the system at the Hospital Clínico Universitario Virgen de La Arrixaca (Murcia, Spain), says: "There is nothing better than being able to rely on a patient-specific solution for each kind of knee surgery. Medacta has more than ten years of experience in patient-specific solutions, and I think that the MyKnee R is a great addition to this range of options. Thanks to the 3D preoperative planning tool and the possibility of accurately and quickly replicating the planning during the surgery with the 3D-printed guides, every surgeon can easily achieve conservative bone cuts, none or minimal alteration of the joint line and an optimized alignment of revision implant components, also when revising failed total knee implants."

MyKnee R is part of Medacta's MySolutions ecosystem of personalized medicine products and technologies. Originally introduced as MyKnee^(R) to address an unmet need for better implant positioning in the total knee replacement market, MySolutions can now also be used in hip (MyHip^(R), MyHip^(R) Planner, MyHip^(R) Verifier), shoulder (MyShoulder^(R)) and spine (MySpine^(R)) procedures. In addition to patient-matched surgical guides, MySolutions also includes advanced planning and verification tools, augmented reality-based personalized execution, patient pathway optimization and clinical data collection and analysis.

Dr. Leon concludes "Medacta has a solution for each specific patient's need, providing a comprehensive implant portfolio that covers unicompartmental knee arthroplasties, with the GMK^(R) UNI and MOTO^(R) partial knee systems, total knee arthroplasties, with the medially-stabilized GMK^(R) Sphere, and also total knee revisions, with the GMK Revision System. These implants are also available with the SensiTiN^TM ceramic-like coating, which offers a hypoallergenic alternative by reducing the release of metal ions into the patient's body. Now, with MyKnee R, also the MySolutions portfolio is complete, and every kind of knee surgery can be managed using Medacta's patient-specific guides."

MyKnee R is also supported by a tailored educational offering. With an international network of expert surgeons, the M.O.R.E. Institute is at the forefront of education on total knee revision techniques and products with personalized high-level educational pathways, supporting surgeons with focused activities as they master revision. With Medacta the surgeon is never alone.

Discover more about MyKnee R and Medacta's knee portfolio.

Contact Medacta International SA Gianluca Olgiati Senior Director Global Marketing Phone: +41 91 696 60 60 media@medacta.ch

About Medacta Medacta is an international company specializing in the design, production, and distribution of innovative orthopaedic products, as well as in the development of accompanying surgical techniques. Established in 1999 in Switzerland, Medacta is active in joint replacement, spine surgery, and sports medicine. Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Medacta's innovation, forged by close collaboration with surgeon leaders globally, began with minimally invasive surgical techniques and has evolved into personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 40 countries.

-----------------------------------------------------------------------------------------------------------------------

End of Media Release

-----------------------------------------------------------------------------------------------------------------------

Language:     English 
Company:      Medacta Group SA 
              Strada Regina 
              6874 Castel San Pietro 
              Switzerland 
Phone:        +41 91 696 6060 
E-mail:       info@medacta.ch 
Internet:     www.medacta.com 
ISIN:         CH0468525222 
Listed:       SIX Swiss Exchange 
EQS News ID:  1241706 
 
End of News   EQS Group News Service 
=------------ 

1241706 2021-10-19

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1241706&application_name=news

(END) Dow Jones Newswires

October 19, 2021 13:00 ET (17:00 GMT)

All news about MEDACTA GROUP SA
11/05Medacta marks its GMK Sphere 10-year anniversary
PU
10/19MEDACTA : extends the personalized medicine concept to total knee revision surgeries with ..
PU
10/19Medacta Extends the Personalized Medicine Concept to Total Knee Revision Surgeries with..
CI
09/29MEDACTA : First Surgery with Medacta's Minimally Invasive M.U.S.T. MC Platform Read More >
PU
09/16MEDACTA : celebrates the milestone of 10,000 Medacta Shoulder System implanted worldwide!
PU
09/14MEDACTA : Credit Suisse Lifts Price Target on Medacta Group, Maintains Neutral Recommendat..
MT
09/10MEDACTA : Swiss Medical Device Maker Medacta's H1 Profit Climbs as All Business Areas Expa..
MT
09/10MEDACTA : Press Release – 2021 Half-Year Results
PU
09/10MEDACTA : reports strong profitability with 31.9% adjusted EBITDA margin in the first seme..
PU
09/10MEDACTA : 2021 Half-Year Presentation
PU
More news
Analyst Recommendations on MEDACTA GROUP SA
More recommendations
Financials
Sales 2021 367 M 415 M 415 M
Net income 2021 58,1 M 65,8 M 65,8 M
Net Debt 2021 76,1 M 86,1 M 86,1 M
P/E ratio 2021 41,5x
Yield 2021 0,62%
Capitalization 2 373 M 2 687 M 2 685 M
EV / Sales 2021 6,67x
EV / Sales 2022 5,84x
Nbr of Employees 1 246
Free-Float 30,5%
Chart MEDACTA GROUP SA
Duration : Period :
Medacta Group SA Technical Analysis Chart | MOVE | CH0468525222 | MarketScreener
Technical analysis trends MEDACTA GROUP SA
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Last Close Price 118,66 €
Average target price 134,50 €
Spread / Average Target 13,4%
EPS Revisions
Managers and Directors
Francesco Siccardi Chief Executive Officer
Corrado Farsetta Chief Financial Officer
Alberto Siccardi Executive Chairman
Victor Waldemar Balli Lead Independent Non-Executive Director
Philippe A. Weber Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
MEDACTA GROUP SA50.68%2 822
ABBOTT LABORATORIES14.23%221 160
MEDTRONIC PLC-2.30%153 906
BECTON, DICKINSON AND COMPANY-2.30%69 432
HOYA CORPORATION27.96%59 234
DEXCOM, INC.61.90%58 016